TGTX FY 2025 Earnings — TG Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

TGTXTG Therapeutics, Inc.

$5B

FY 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$616M+87.3% YoY

Gross Profit

$515M83.6% margin

Operating Income

$123M20.0% margin

Net Income

$447M72.6% margin

EPS (Diluted)

$2.77

Cash Flow

Operating Cash Flow

-$25M

Free Cash Flow

-$25M

Stock-Based Comp.

$65M

Balance Sheet

Total Assets

$1.1B

Total Liabilities

$415M

Stockholders' Equity

$648M

Cash & Equivalents

$79M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$616M	$329M	+87.3%
Gross Profit	$515M	$291M	+77.4%
Operating Income	$123M	$42M	+194.1%
Net Income	$447M	$23M	+1812.4%